Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov:61:103045.
doi: 10.1016/j.ebiom.2020.103045. Epub 2020 Oct 7.

Tocilizumab is recommended for the treatment of severe COVID-19

Affiliations
Comment

Tocilizumab is recommended for the treatment of severe COVID-19

Yonggang Zhou et al. EBioMedicine. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

H.M.W. and Y.G.Z. are inventors on patent application (CN202010103449.6) submitted by the University of Science and Technology of China that covers the new use of anti-IL-6R antibody for COVID-19.

Comment on

References

    1. Mar Masiá MF, Padilla S, Ortega P. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study. E Bio Med. 2020 doi: 10.1016/j.ebiom.2020.102999. - DOI - PMC - PubMed
    1. Zhou Y, Fu B, Zheng X. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998–1002. - PMC - PubMed
    1. Manne BK, Denorme F, Middleton EA. Platelet gene expression and function in COVID-19 patients. Blood. 2020 blood.2020007214. - PMC - PubMed
    1. Xu X, Han M, Li T. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. - PMC - PubMed
    1. Guaraldi G, Meschiari M, Cozzi-Lepri A. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. - PMC - PubMed

Substances